Eli Lilly and Company Press Releases

LLY 
$62.84
*  
0.31
0.5%
Get LLY Alerts
*Delayed - data as of Jul. 11, 2014  -  Find a broker to begin trading LLY now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Lilly for Better Health™ expands website's non-product-branded health education resources, focuses on healthy behavior skills
7/10/2014 1:00:00 PM - PR Newswire

Lilly Confirms Date and Conference Call for Second-Quarter 2014 Financial Results Announcement
7/9/2014 12:00:00 PM - PR Newswire

Lilly to Showcase Data from its Alzheimer's Disease Portfolio at the Alzheimer's Association International Conference 2014 (AAIC 2014)
7/8/2014 8:00:00 AM - PR Newswire

NASCAR Driver Ryan Reed Finishes Fourth at the Subway Firecracker 250 at Daytona International Speedway
7/7/2014 4:35:00 PM - PR Newswire

Yabao Pharmaceuticals Enters Innovative Partnership with Eli Lilly and Company to Develop Diabetes Treatment
7/7/2014 9:20:00 AM - PR Newswire

CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European Union
6/27/2014 8:00:00 AM - PR Newswire

CHMP Recommends Lilly and Boehringer Ingelheim's Investigational New Insulin Glargine Product for Approval in the European Union
6/27/2014 8:00:00 AM - PR Newswire

Diabetes Scholars Foundation Announces 2014 Scholarship Recipients
6/25/2014 9:00:00 AM - PR Newswire

Eli Lilly and Company Collaborates with Public and Private Healthcare Organizations to Provide Medical Students an Opportunity to Explore Healthcare Outside the Traditional Learning Environment
6/23/2014 8:00:00 AM - PR Newswire

Pharma Equities Technical Coverage -- Research on Eli Lilly, AstraZeneca, Allergan, and Provectus Biopharma
6/23/2014 7:20:00 AM - PR Newswire

Type 2 diabetes: Boehringer Ingelheim and Eli Lilly and Company announce resubmission of New Drug Application for empagliflozin to FDA
6/17/2014 3:53:00 PM - PR Newswire

Lilly Announces Detailed Results from Two Phase III Studies Testing Both Doses of Dulaglutide vs. Insulin Glargine
6/16/2014 6:15:00 PM - PR Newswire

Lilly Declares Third-Quarter 2014 Dividend
6/16/2014 2:15:00 PM - PR Newswire

Type 2 diabetes: Investigational compound empagliflozin as an add-on therapy significantly reduced blood glucose and body weight in two newly presented phase III trials
6/16/2014 11:45:00 AM - PR Newswire

Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials
6/15/2014 3:00:00 PM - PR Newswire

Lilly's Once-Weekly Dulaglutide Shows Similar Reductions in Average Blood Glucose Levels as Once-Daily Liraglutide in Head-to-Head Trial
6/14/2014 1:00:00 PM - PR Newswire

Lilly's Basal Insulin Peglispro Shows Novel Mechanism of Action
6/14/2014 1:00:00 PM - PR Newswire

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar Safety and Efficacy Profile to Lantus®
6/14/2014 1:00:00 PM - PR Newswire

Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
6/11/2014 8:00:00 AM - PR Newswire

Lilly to Participate in Goldman Sachs Global Healthcare Conference
6/9/2014 10:00:00 AM - PR Newswire

Lilly to Present New Clinical Data from Diabetes Portfolio with 76 Abstracts at the 74th American Diabetes Association Scientific Sessions®
6/9/2014 9:00:00 AM - PR Newswire

Diabetes: Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 43 Presentations at the 74th American Diabetes Association Scientific Sessions®
6/9/2014 9:00:00 AM - PR Newswire

Lilly Diabetes Adds NASCAR Nationwide Series Driver Ryan Reed to Annual Diabetes Summer Camp Tour
6/9/2014 8:30:00 AM - PR Newswire

KDC Solar and Lilly Commence Commercial Operations on 9.95-Megawatt Solar Panel System
6/5/2014 3:00:00 PM - PR Newswire

Lilly's CYRAMZA™ (ramucirumab) Significantly Improves Overall Survival In Phase III Non-Small Cell Lung Cancer Study
6/2/2014 6:30:00 PM - PR Newswire